Action Abivax - ABVX

Abivax (ABVX) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

122,90

( 0,24% )

Prix Achat

122,00

Prix Vente

123,90

Volume échangé

100 898

Volume moyen (3 m)

308 651 €

Volume financier

120,60 Fourchette du Jour 125,00

57,50 Plage de 52 semaines 139,00

Cap du marché

9,808B

Valeur d'Entreprise

10,316B

Clôture Veille

122,60

Ouverture

124,10

Dernière Transaction

122.9

Dernière heure de transaction

VWAP

Chiffre d'affairess (LTM)

4,92M

Bénéfice net (LTM)

-332,2M

Actions en circulation

79 800 669

Flottant (%)

60,69%

Détention Institutionnelle (%)

132,72%

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-29,84

Ratio Cours/Ventes (P/S)

2,19k

Bénéfice par action (BPA)

-4,52

Bêta

-0,21

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical devel... ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. Show more

Secteur

Health Care

Industrie

Site Web

www.abivax.com

Siège social

Paris, France

Fondé

2026

Abivax est coté dans le secteur Health Care de la Euronext avec le ticker ABVX. Le dernier cours de clôture d'Abivax était de 122,60 €. Au cours de la dernière année, les actions de Abivax ont été négociées dans une fourchette de prix de 57,50 € à 139,00 €.

Abivax compte actuellement 79 800 669 actions en circulation. La capitalisation boursière d'Abivax est de 9,81 € milliard. Abivax a un ratio cours/bénéfice (ratio PE) de -29.84.

Abivax annonce la réalisation de son offre au public de 920 millions de dollars

ABIVAX Abivax annonce la réalisation de son offre au public de 920 millions de dollars 06-Juil-2026 / 22:05...

Abivax Announces Closing of $920 Million Public Offering

Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax...

Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l’Offre à 920 M$ (807 M€)

ABIVAX Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de...

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of...

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris

ABIVAX Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris 01-Juil-2026 /...

Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American...

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 –...

Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares

ABIVAX Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€...

Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary...

Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris

ABIVAX Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-5	-3.90930414386	127.9	139	120.5	404889	130.44367006	DE
4	36.9	42.9069767442	86	139	76.95	278786	105.9867864	DE
12	18.2	17.3829990449	104.7	139	60.45	342865	99.62218476	DE
26	18.1	17.2709923664	104.8	139	60.45	267619	101.4240744	DE
52	61.9	101.475409836	61	139	57.5	192670	98.13588518	DE
156	106.82	664.303482587	16.08	139	4.51	83111	69.81175033	DE
260	93.8	322.336769759	29.1	139	4.51	60465	58.53891866	DE

ABVX - Frequently Asked Questions (FAQ)

What is the current Abivax share price?

The current share price of Abivax is 122,90 €

How many Abivax shares are in issue?

Abivax has 79 800 669 shares in issue

What is the market cap of Abivax?

The market capitalisation of Abivax is EUR 9,81B

What is the 1 year trading range for Abivax share price?

Abivax has traded in the range of 57,50 € to 139,00 € during the past year

What is the PE ratio of Abivax?

The price to earnings ratio of Abivax is -29,84

What is the cash to sales ratio of Abivax?

The cash to sales ratio of Abivax is 2,19k

What is the registered address of Abivax?

The registered address for Abivax is 7-11 Boulevard Haussmann, Paris, Ile-de-France, 75009

What is the Abivax website address?

The website address for Abivax is www.abivax.com

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Abivax (ABVX)

Abivax (ABVX) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Abivax

ABVX Dernières nouvelles

Abivax annonce la réalisation de son offre au public de 920 millions de dollars

Abivax Announces Closing of $920 Million Public Offering

Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l’Offre à 920 M$ (807 M€)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris

Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares

Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris

Abivax Announces Closing of $920 Million Public Offering

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax Announces Launch of Public Offering of American Depositary Shares

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

ABVX - Frequently Asked Questions (FAQ)

ABVX Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités